Drug updated on 9/4/2024
Dosage Form | Tablet (oral; 200 mg, 250 mg, 300 mg) |
Drug Class | Poly (ADP-ribose) polymerase (PARP) inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
Latest News
Summary
- Rubraca (rucaparib) is indicated for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It is also indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
- This summary is based on the review of 12 systematic review(s)/meta-analysis(es). [1-12]
- In metastatic castration-resistant prostate cancer (mCRPC), 43% of the overall population achieved a PSA decline of ≥ 50% (95% CI 0.32-0.54), with BRCA2 patients showing a higher response rate of 66% (95% CI 0.57-0.7). Overall survival was 15.9 months (95% CI 12.9-19.0) in the general population and 23.4 months (95% CI 22.8-24.1) in BRCA2 patients.
- In recurrent ovarian cancer treated with PARP inhibitors (PARPi) for maintenance therapy, the progression-free survival (PFS) was significantly improved, with a hazard ratio (HR) of 0.34 (CI 0.29-0.40) in the overall population and 0.24 (CI 0.18-0.31) in BRCA-mutant patients.
- Newly diagnosed ovarian cancer patients receiving PARPi showed a PFS benefit, with an HR of 0.46 (CI 0.30-0.71) for the overall population and 0.36 (CI 0.29-0.44) for the BRCAm population.
- BRCA-mutant ovarian cancer patients demonstrated significant PFS improvements with PARPi, with no statistically significant differences observed between Olaparib, Niraparib, and Rucaparib in terms of PFS or overall survival across different subpopulations.
- The incidence of any grade adverse events (AEs) in mCRPC was 50% (95% CI 0.39-0.60), with 50% (95% CI 0.39-0.60) of patients experiencing grade 3 or 4 AEs. Hematological adverse events, particularly anemia, were the most common (21.5%).
- In ovarian cancer, there was an increased risk of severe adverse events with PARPi compared to placebo, notably hematological AEs such as thrombocytopenia and neutropenia. Niraparib was associated with a higher risk of grade 3 and 4 thrombocytopenia and any grade neutropenia compared to other PARPi, while Olaparib may present fewer grade 3 or higher AEs compared to Niraparib and Rucaparib.
- Rucaparib and Niraparib had higher incidences of grade 3 or 4 adverse events compared to Olaparib, specifically in hematological outcomes such as thrombocytopenia and neutropenia.
- In mCRPC, BRCA2 patients exhibited higher PSA decline rates (66%, 95% CI 0.57-0.7) and overall survival (23.4 months, 95% CI 22.8-24.1) compared to the overall mCRPC population. In ovarian cancer, PARPi treatment significantly improved PFS in BRCA mutant subgroups, with both germline (HR 0.23, 95% CI 0.18-0.30) and somatic mutations showing similar benefits. Homologous recombination deficient (HRD) patients also showed substantial PFS improvement, albeit less pronounced than BRCA mutants, while homologous recombination proficient (HRP) patients benefited to a lesser extent.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Rubraca (rucaparib) Prescribing Information. | 2022 | FDA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. | 2023 | Annals of Oncology |
Guidelines for management of treatment-emergent adverse events during rucaparib treatment of patients with metastatic castration-resistant prostate cancer. | 2022 | Cancer Management and Research |
PARP inhibitors in the management of ovarian cancer: ASCO guideline. | 2021 | Journal of Clinical Oncology |
FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA‐mutated metastatic castrate‐resistant prostate cancer. | 2020 | Society of Translational Oncology |
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting. | 2020 | Therapeutic Advances in Medical Oncology |